
Allena Pharmaceuticals ALNA
Quarterly report 2022-Q2
added 08-15-2022
Allena Pharmaceuticals General and Administrative Expenses 2011-2026 | ALNA
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Allena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.7 M | 11.6 M | 9.68 M | 8.64 M | 5.43 M | 4.08 M | 2.36 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.7 M | 2.36 M | 7.78 M |
Quarterly General and Administrative Expenses Allena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.94 M | 3.8 M | - | 3.41 M | 3.6 M | 3.56 M | - | 2.97 M | 2.75 M | 2.88 M | - | 2.53 M | 2.75 M | 2.43 M | - | 2.39 M | 2.28 M | 2.04 M | - | 1.41 M | 1.02 M | 1.19 M | - | 839 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.8 M | 839 K | 2.49 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.05 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
2.31 M | - | 1.35 % | $ 17.8 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 16.88 | -2.43 % | $ 789 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
Compugen Ltd.
CGEN
|
10.9 M | $ 2.79 | -8.09 % | $ 261 M | ||
|
Coherus BioSciences
CHRS
|
101 M | $ 1.6 | -2.15 % | $ 187 M | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
19.9 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
46.1 M | $ 7.56 | -3.45 % | $ 207 M | ||
|
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
24.5 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
5.69 M | - | -32.59 % | $ 7.61 M | ||
|
Esperion Therapeutics
ESPR
|
166 M | $ 3.13 | 0.32 % | $ 651 M | ||
|
Exelixis
EXEL
|
519 M | $ 50.41 | -1.36 % | $ 13.7 B | ||
|
Fortress Biotech
FBIO
|
96.4 M | $ 2.43 | 5.65 % | $ 67.8 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
12.4 M | $ 23.1 | -3.57 % | $ 299 M | ||
|
Fennec Pharmaceuticals
FENC
|
28.3 M | $ 9.76 | 5.63 % | $ 279 M | ||
|
AbCellera Biologics
ABCL
|
83.2 M | $ 4.09 | -7.05 % | $ 1.22 B | ||
|
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.59 | - | $ 423 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
BioNTech SE
BNTX
|
514 M | $ 89.16 | -3.08 % | $ 21.5 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | ||
|
Galectin Therapeutics
GALT
|
5.8 M | $ 2.22 | -5.74 % | $ 142 M | ||
|
Gilead Sciences
GILD
|
5.77 B | $ 130.07 | -1.51 % | $ 162 B | ||
|
Genmab A/S
GMAB
|
661 M | $ 26.8 | -0.37 % | $ 1.73 B | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.41 | -2.25 % | $ 5.61 M | ||
|
Aeterna Zentaris
AEZS
|
10.1 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
Grifols, S.A.
GRFS
|
1.26 B | $ 7.74 | -0.64 % | $ 5.26 B | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
186 K | $ 0.72 | -1.05 % | $ 32.9 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Eton Pharmaceuticals
ETON
|
35.8 M | $ 29.69 | -0.92 % | $ 799 M | ||
|
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
275 M | $ 21.51 | -0.3 % | $ 2.74 B |